View Older Stories View More Recent Stories

Oct 5, 2017 07:32AM Biogen (BIIB) Reports SPINRAZA (Nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function
Oct 5, 2017 07:30AM Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
Sep 26, 2017 04:01PM Biogen to Report Third Quarter 2017 Financial Results on October 24, 2017
Sep 25, 2017 09:23AM Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
Sep 12, 2017 07:30AM Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
Sep 6, 2017 04:01PM Biogen to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Aug 28, 2017 07:30AM Biogen (BIIB) Announces New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Aug 28, 2017 07:30AM Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Aug 24, 2017 07:05PM IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
Jul 31, 2017 09:00AM Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
Jul 25, 2017 06:30AM Biogen Reports Record Quarterly Revenues of $3.1 Billion, Raises Full Year Revenue Guidance
Jul 24, 2017 04:15PM Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
Jul 14, 2017 07:32AM Biogen (BIIB) Plans to Present Data at AAIC
Jul 14, 2017 07:30AM Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
Jul 10, 2017 07:30AM Biogen Appoints Amy Chevalier Efantis Vice President of Government Affairs
Jun 29, 2017 07:33AM Biogen (BIIB) Says New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA in SMA
Jun 29, 2017 07:30AM New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA® (nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
Jun 28, 2017 07:30AM Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
Jun 23, 2017 07:57AM Biogen (BIIB) Announces IMRALDI, Biosimilar Candidate Referencing Humira, Granted Positive Opinion by CHMP
Jun 23, 2017 07:55AM Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use
Jun 20, 2017 04:01PM Biogen to Report Second Quarter 2017 Financial Results and Strategic Update on July 25, 2017
Jun 20, 2017 07:30AM Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer
Jun 14, 2017 07:30AM Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations
Jun 13, 2017 04:16PM Biogen (BIIB) CFO to Leave to Join Another Biopharmaceutical Company
Jun 13, 2017 04:15PM Biogen Announces Management Change
Jun 1, 2017 07:31AM Biogen (BIIB) Says SPINRAZA Approved in EU as First Treatment for Spinal Muscular Atrophy
Jun 1, 2017 07:30AM SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy
May 31, 2017 05:00PM Biogen Announces Webcast of Virtual Annual Meeting of Stockholders
May 24, 2017 05:59AM Biogen (BIIB) FAMPYRA Receives EU Approval for Standard Marketing Authorization for Improvement of Walking in People with MS
May 24, 2017 01:30AM Biogen’s FAMPYRA® Granted Standard Marketing Authorization in European Union for Improvement of Walking in People with MS
May 17, 2017 04:01PM Biogen to Present at the Bernstein 33rd Annual Strategic Decisions Conference
May 15, 2017 07:31AM Biogen (BIIB) to Acquire Remedy Pharmaceuticals' Phase 3 Candidate CIRARA for Large Hemispheric Stroke
May 15, 2017 07:30AM Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke
Apr 25, 2017 06:59AM Biogen Reports First Quarter 2017 Revenues of $2.8 Billion
Apr 24, 2017 07:39AM Biogen (BIIB) Says TECFIDERA and TYSABRI Data Shows Improved Outcomes with Early MS Treatment
Apr 24, 2017 07:32AM Biogen (BIIB) Says Final Phase 3 Study Data Show SPINRAZA Significantly Improved Motor Function in Children with Later-Onset SMA
Apr 24, 2017 07:30AM TECFIDERA® and TYSABRI® Data Demonstrate Improved Outcomes with Early MS Treatment
Apr 24, 2017 07:30AM Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Apr 21, 2017 02:02PM Biogen (BIIB) Report Positive CHMP Opinion on SPINRAZA for Treatment of Spinal Muscular Atrophy
Apr 21, 2017 02:00PM Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Apr 18, 2017 07:33AM Biogen (BIIB) to Present Data on Neurology Research Programs and Portfolio at AAN
Apr 18, 2017 07:30AM Biogen Highlights Advances from Its Neurology Research Programs and Portfolio of Innovative Medicines at AAN Congress
Apr 13, 2017 07:10AM Biogen (BIIB) Confirms Agreement to License Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb (BMY)
Apr 13, 2017 07:00AM Bristol-Myers Squibb (BMY) Enters Agreements to License Anti-eTau, Anti-Myostatin Compounds to Biogen (BIIB), Roche
Apr 13, 2017 07:00AM Biogen Licenses Phase 2 Anti-Tau Antibody from Bristol-Myers Squibb
Apr 13, 2017 06:59AM Bristol-Myers Squibb Enters into Separate Agreements with Biogen and Roche to License Anti-eTau and Anti-Myostatin Compounds, Respectively
Mar 28, 2017 07:31AM Biogen (BIIB) to Present Alzheimer's and Parkinson's Data at AD/PD
Mar 28, 2017 07:30AM Biogen to Present Data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases
Mar 27, 2017 04:01PM Biogen to Report First Quarter 2017 Financial Results on April 25, 2017
Mar 16, 2017 07:00AM Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development
View More Recent Stories View Older Stories